Novo Nordisk's high-dose 7.2 mg semaglutide pen began shipping to US pharmacies on April 7, 2026, after the FDA approved it via the new National Priority Voucher program in March. Q1 2026 earnings posted today confirm the rollout is moving — but for research peptide buyers, the more interesting question is what 20.7% mean weight loss means for your dosing protocol.
What Was Approved and When
The FDA cleared the 7.2 mg dose on March 19, 2026, using one of four "priority voucher" approvals issued under the new accelerated framework. US shipments began April 7. Today's Q1 2026 earnings update from Novo Nordisk confirmed the launch is on track and that retail availability now mirrors the existing 2.4 mg supply chain.
The new pen is a redesigned device — same molecule, three times the maximum dose. Patients titrate up the same way they do on 2.4 mg (0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg over roughly 16 weeks), then continue stepping up to 4.8 mg and finally 7.2 mg. Total titration to the maximum dose now takes around 32 weeks.
Pricing as of launch sits in line with the 2.4 mg pen — list price north of $1,300/month before insurance or savings card. The savings card brings commercial-plan copays down toward $25 for the lower doses, but the higher 7.2 mg tier is where the pricing structure has not been fully spelled out yet.
STEP UP Trial: The 20.7% Number
The approval rests on the 72-week STEP UP trial, which enrolled approximately 1,400 adults with obesity. Three arms: 7.2 mg, 2.4 mg, and placebo.
| Arm | Mean weight loss at 72 weeks |
|---|---|
| Semaglutide 7.2 mg (per-protocol) | 20.7% |
| Semaglutide 2.4 mg (per-protocol) | 17.5% |
| Placebo | 2.4% |
About 31.2% of participants on 7.2 mg achieved at least 25% weight loss — a number that previously belonged almost exclusively to triple-agonist territory (retatrutide hit 28.7% in TRIUMPH-4 on the 12 mg dose). The HD dose closes some of that gap with a single agonist that already has a five-year safety record.
A companion STEP UP T2D trial enrolled adults with obesity and type 2 diabetes. Weight loss was lower in the diabetic cohort — consistent with what every GLP-1 trial has shown going back to STEP 2.
The catch: 20.7% is the per-protocol number, meaning patients who stayed on treatment and adhered to the regimen. Intent-to-treat analysis (which counts everyone who started, including dropouts) usually pulls average loss down 3-5 percentage points. Real-world adherence is also lower than trial adherence. Plan accordingly.
What This Means for Research Peptide Buyers
The high-dose approval changes nothing about what's in the vial — it's still semaglutide. But it does three things that matter:
1. Validates higher protocol doses. Forum and Reddit reports of researchers running 3-5 mg/week to push past plateaus now have phase-3 cover. STEP UP shows the molecule keeps working at higher doses without a new safety signal severe enough to block approval. The most common adverse events at 7.2 mg were the usual GI cluster (nausea, vomiting, diarrhea) — same as 2.4 mg, just more frequent.
2. Reframes vial economics. A single 10 mg research peptide vial reconstituted with 1 mL of bacteriostatic water gives you 10 mg total. At a 7.2 mg/week protocol, that's roughly a 9-day supply per vial — not the 4-week supply you get titrating at 2.4 mg/week. Higher dose = faster vial burn. Either buy larger vials (15-25 mg) or expect to order more often. See the semaglutide reconstitution guide for the dilution math.
3. Widens the price gap. Branded high-dose pens at $1,300+/month vs. research peptide vials at $40-90 per 10 mg is the biggest absolute-dollar gap GLP-1 buyers have ever seen. The relative gap was already large at the 2.4 mg dose. At 7.2 mg the gap roughly triples in absolute terms because you need three times the molecule.
For context on where to source: the /best/semaglutide page ranks vendors by price-per-mg, third-party COA testing, and shipping reliability. The biggest 10-mg vial discounts right now are stacked on the deals page.
